Real-World Effectiveness and Safety of Selective JAK Inhibitors in Ulcerative Colitis and Crohn’s Disease: A Retrospective, Multicentre Study
Background/Objectives: Data on the real-world effectiveness and safety of selective JAK inhibitors (JAKis) in ulcerative colitis (UC) and Crohn’s disease (CD) are limited. Methods: We conducted a multicentre, retrospective study to assess clinical, biochemical, and endoscopic outcomes of selective J...
Gespeichert in:
Veröffentlicht in: | Journal of clinical medicine 2024-12, Vol.13 (24), p.7804 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 24 |
container_start_page | 7804 |
container_title | Journal of clinical medicine |
container_volume | 13 |
creator | Farkas, Bernadett Bessissow, Talat Limdi, Jimmy K Sethi-Arora, Karishma Kagramanova, Anna Knyazev, Oleg Bezzio, Cristina Armuzzi, Alessandro Lukas, Milan Michalopoulos, George Chaskova, Elena Savarino, Edoardo Vincenzo Castiglione, Fabiana Rispo, Antonio Schäfer, Eszter Saibeni, Simone Filip, Rafal Attauabi, Mohamed Fousekis, Fotios S Bacsur, Péter Resál, Tamás Bálint, Anita Ivány, Emese Szepes, Zoltán Bősze, Zsófia Fábián, Anna Bor, Renáta Farkas, Klaudia Lakatos, Peter L Molnár, Tamás |
description | Background/Objectives: Data on the real-world effectiveness and safety of selective JAK inhibitors (JAKis) in ulcerative colitis (UC) and Crohn’s disease (CD) are limited. Methods: We conducted a multicentre, retrospective study to assess clinical, biochemical, and endoscopic outcomes of selective JAKis in bio-experienced UC and CD. Results: A total of 246 patients (mean age: 40.5 ± 14.5 years; 131 UC and 115 CD) were included with a median follow-up of 7.5 months. Among the CD patients receiving upadacitinib (n = 115), 76.2% achieved clinical remission (CR) at week 12. Furthermore, 59.5% of the upadacitinib-treated UC patients (n = 100) experienced CR at week 8. Corticosteroid-free CR (CSFCR) was achieved by 76.9% of the CD patients and 80.6% of the UC patients at week 24, while 50.0% and 36.1% experienced endoscopic remission. At week 52, 66.7% of the CD and 86.2% of the UC patients achieved CSFCR, whereas 54.5% and 52.9% had endoscopic remission. In UC, the effectiveness of upadacitinib was not compromised by prior tofacitinib failure, while the upadacitinib-treated CD patients with stricturing and penetrating disease were less likely to achieve CR by the end of the induction phase (p = 0.04). C-reactive protein (p[CD] < 0.0001; p[UC] < 0.0001) and faecal calprotectin (p[CD] < 0.0001; p[UC] = 0.02) decreased significantly in both patient groups as early as week 2. Among the filgotinib-treated UC patients (n = 31), 28.6% were in CR at week 12. At week 24 and 52, 59.1% and 60% achieved CSFCR, while 0.0% and 20.0% had endoscopic remission. Both C-reactive protein (p = 0.04) and faecal calprotectin (p = 0.04) decreased significantly by week 12. Hyperlipidaemia (9.7–9.8%) was the most common adverse event. Conclusions: Selective JAKis are rapidly effective and safe for treating refractory, moderate-to-severe CD and UC. |
doi_str_mv | 10.3390/jcm13247804 |
format | Article |
fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_3149643575</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A821838011</galeid><sourcerecordid>A821838011</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1684-ef38d65a0824d469012b77e9e5b03ecdd7adf3c2bed0ee5f2c504bf4b1aa2b6d3</originalsourceid><addsrcrecordid>eNptUUtLxDAQLqKgqCf_QMCjVvNqm_W2rO8Hgqt4LGky0SzdZE2ywt78B579e_4SqxVUcOYww3yPgZks2yJ4j7EB3p-oKWGUVwLzpWyN4qrKMRNs-Ve_mm3GOMFdCMEpqday1xuQbX7vQ6vRkTGgkn0GBzEi6TQaSwNpgbxBY2h7DJ0PL9CZe7SNTT5EZB26axUE-QWOfGuT7cWj4B_d-8tbRIc2goxwgIboBlLwcdZ77aKreZusApcCoHGa68VGtmJkG2Hzu65nd8dHt6PT_PL65Gw0vMwVKQXPwTChy0JiQbnm5QAT2lQVDKBoMAOldSW1YYo2oDFAYagqMG8Mb4iUtCk1W8-2e99Z8E9ziKme-Hlw3cqaET4oOSuq4of1IFuorTM-BammNqp6KCgRTGBCOtbeP6wuNUyt8g6M7eZ_BDu9QHW3iAFMPQt2KsOiJrj-_GX965fsA44hkqM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3149643575</pqid></control><display><type>article</type><title>Real-World Effectiveness and Safety of Selective JAK Inhibitors in Ulcerative Colitis and Crohn’s Disease: A Retrospective, Multicentre Study</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>PubMed Central</source><creator>Farkas, Bernadett ; Bessissow, Talat ; Limdi, Jimmy K ; Sethi-Arora, Karishma ; Kagramanova, Anna ; Knyazev, Oleg ; Bezzio, Cristina ; Armuzzi, Alessandro ; Lukas, Milan ; Michalopoulos, George ; Chaskova, Elena ; Savarino, Edoardo Vincenzo ; Castiglione, Fabiana ; Rispo, Antonio ; Schäfer, Eszter ; Saibeni, Simone ; Filip, Rafal ; Attauabi, Mohamed ; Fousekis, Fotios S ; Bacsur, Péter ; Resál, Tamás ; Bálint, Anita ; Ivány, Emese ; Szepes, Zoltán ; Bősze, Zsófia ; Fábián, Anna ; Bor, Renáta ; Farkas, Klaudia ; Lakatos, Peter L ; Molnár, Tamás</creator><creatorcontrib>Farkas, Bernadett ; Bessissow, Talat ; Limdi, Jimmy K ; Sethi-Arora, Karishma ; Kagramanova, Anna ; Knyazev, Oleg ; Bezzio, Cristina ; Armuzzi, Alessandro ; Lukas, Milan ; Michalopoulos, George ; Chaskova, Elena ; Savarino, Edoardo Vincenzo ; Castiglione, Fabiana ; Rispo, Antonio ; Schäfer, Eszter ; Saibeni, Simone ; Filip, Rafal ; Attauabi, Mohamed ; Fousekis, Fotios S ; Bacsur, Péter ; Resál, Tamás ; Bálint, Anita ; Ivány, Emese ; Szepes, Zoltán ; Bősze, Zsófia ; Fábián, Anna ; Bor, Renáta ; Farkas, Klaudia ; Lakatos, Peter L ; Molnár, Tamás</creatorcontrib><description>Background/Objectives: Data on the real-world effectiveness and safety of selective JAK inhibitors (JAKis) in ulcerative colitis (UC) and Crohn’s disease (CD) are limited. Methods: We conducted a multicentre, retrospective study to assess clinical, biochemical, and endoscopic outcomes of selective JAKis in bio-experienced UC and CD. Results: A total of 246 patients (mean age: 40.5 ± 14.5 years; 131 UC and 115 CD) were included with a median follow-up of 7.5 months. Among the CD patients receiving upadacitinib (n = 115), 76.2% achieved clinical remission (CR) at week 12. Furthermore, 59.5% of the upadacitinib-treated UC patients (n = 100) experienced CR at week 8. Corticosteroid-free CR (CSFCR) was achieved by 76.9% of the CD patients and 80.6% of the UC patients at week 24, while 50.0% and 36.1% experienced endoscopic remission. At week 52, 66.7% of the CD and 86.2% of the UC patients achieved CSFCR, whereas 54.5% and 52.9% had endoscopic remission. In UC, the effectiveness of upadacitinib was not compromised by prior tofacitinib failure, while the upadacitinib-treated CD patients with stricturing and penetrating disease were less likely to achieve CR by the end of the induction phase (p = 0.04). C-reactive protein (p[CD] < 0.0001; p[UC] < 0.0001) and faecal calprotectin (p[CD] < 0.0001; p[UC] = 0.02) decreased significantly in both patient groups as early as week 2. Among the filgotinib-treated UC patients (n = 31), 28.6% were in CR at week 12. At week 24 and 52, 59.1% and 60% achieved CSFCR, while 0.0% and 20.0% had endoscopic remission. Both C-reactive protein (p = 0.04) and faecal calprotectin (p = 0.04) decreased significantly by week 12. Hyperlipidaemia (9.7–9.8%) was the most common adverse event. Conclusions: Selective JAKis are rapidly effective and safe for treating refractory, moderate-to-severe CD and UC.</description><identifier>ISSN: 2077-0383</identifier><identifier>EISSN: 2077-0383</identifier><identifier>DOI: 10.3390/jcm13247804</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>C-reactive protein ; Care and treatment ; Colitis ; Crohn's disease ; Disease ; Diseases ; Drug therapy ; Ecuador ; Endoscopy ; Ethics ; Hungary ; Italy ; Kinases ; Medical research ; Medicine, Experimental ; Patient outcomes ; Patients ; Remission (Medicine) ; Russia ; Steroids ; Tofacitinib ; Ulcerative colitis</subject><ispartof>Journal of clinical medicine, 2024-12, Vol.13 (24), p.7804</ispartof><rights>COPYRIGHT 2024 MDPI AG</rights><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1684-ef38d65a0824d469012b77e9e5b03ecdd7adf3c2bed0ee5f2c504bf4b1aa2b6d3</cites><orcidid>0000-0002-3948-6488 ; 0000-0003-0323-7030 ; 0009-0007-8816-0138 ; 0000-0002-1454-2412 ; 0000-0002-3187-2894 ; 0000-0001-5677-2534 ; 0000-0002-3818-6205 ; 0000-0002-8534-0068 ; 0000-0003-1572-0118 ; 0000-0002-5954-151X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27915,27916</link.rule.ids></links><search><creatorcontrib>Farkas, Bernadett</creatorcontrib><creatorcontrib>Bessissow, Talat</creatorcontrib><creatorcontrib>Limdi, Jimmy K</creatorcontrib><creatorcontrib>Sethi-Arora, Karishma</creatorcontrib><creatorcontrib>Kagramanova, Anna</creatorcontrib><creatorcontrib>Knyazev, Oleg</creatorcontrib><creatorcontrib>Bezzio, Cristina</creatorcontrib><creatorcontrib>Armuzzi, Alessandro</creatorcontrib><creatorcontrib>Lukas, Milan</creatorcontrib><creatorcontrib>Michalopoulos, George</creatorcontrib><creatorcontrib>Chaskova, Elena</creatorcontrib><creatorcontrib>Savarino, Edoardo Vincenzo</creatorcontrib><creatorcontrib>Castiglione, Fabiana</creatorcontrib><creatorcontrib>Rispo, Antonio</creatorcontrib><creatorcontrib>Schäfer, Eszter</creatorcontrib><creatorcontrib>Saibeni, Simone</creatorcontrib><creatorcontrib>Filip, Rafal</creatorcontrib><creatorcontrib>Attauabi, Mohamed</creatorcontrib><creatorcontrib>Fousekis, Fotios S</creatorcontrib><creatorcontrib>Bacsur, Péter</creatorcontrib><creatorcontrib>Resál, Tamás</creatorcontrib><creatorcontrib>Bálint, Anita</creatorcontrib><creatorcontrib>Ivány, Emese</creatorcontrib><creatorcontrib>Szepes, Zoltán</creatorcontrib><creatorcontrib>Bősze, Zsófia</creatorcontrib><creatorcontrib>Fábián, Anna</creatorcontrib><creatorcontrib>Bor, Renáta</creatorcontrib><creatorcontrib>Farkas, Klaudia</creatorcontrib><creatorcontrib>Lakatos, Peter L</creatorcontrib><creatorcontrib>Molnár, Tamás</creatorcontrib><title>Real-World Effectiveness and Safety of Selective JAK Inhibitors in Ulcerative Colitis and Crohn’s Disease: A Retrospective, Multicentre Study</title><title>Journal of clinical medicine</title><description>Background/Objectives: Data on the real-world effectiveness and safety of selective JAK inhibitors (JAKis) in ulcerative colitis (UC) and Crohn’s disease (CD) are limited. Methods: We conducted a multicentre, retrospective study to assess clinical, biochemical, and endoscopic outcomes of selective JAKis in bio-experienced UC and CD. Results: A total of 246 patients (mean age: 40.5 ± 14.5 years; 131 UC and 115 CD) were included with a median follow-up of 7.5 months. Among the CD patients receiving upadacitinib (n = 115), 76.2% achieved clinical remission (CR) at week 12. Furthermore, 59.5% of the upadacitinib-treated UC patients (n = 100) experienced CR at week 8. Corticosteroid-free CR (CSFCR) was achieved by 76.9% of the CD patients and 80.6% of the UC patients at week 24, while 50.0% and 36.1% experienced endoscopic remission. At week 52, 66.7% of the CD and 86.2% of the UC patients achieved CSFCR, whereas 54.5% and 52.9% had endoscopic remission. In UC, the effectiveness of upadacitinib was not compromised by prior tofacitinib failure, while the upadacitinib-treated CD patients with stricturing and penetrating disease were less likely to achieve CR by the end of the induction phase (p = 0.04). C-reactive protein (p[CD] < 0.0001; p[UC] < 0.0001) and faecal calprotectin (p[CD] < 0.0001; p[UC] = 0.02) decreased significantly in both patient groups as early as week 2. Among the filgotinib-treated UC patients (n = 31), 28.6% were in CR at week 12. At week 24 and 52, 59.1% and 60% achieved CSFCR, while 0.0% and 20.0% had endoscopic remission. Both C-reactive protein (p = 0.04) and faecal calprotectin (p = 0.04) decreased significantly by week 12. Hyperlipidaemia (9.7–9.8%) was the most common adverse event. Conclusions: Selective JAKis are rapidly effective and safe for treating refractory, moderate-to-severe CD and UC.</description><subject>C-reactive protein</subject><subject>Care and treatment</subject><subject>Colitis</subject><subject>Crohn's disease</subject><subject>Disease</subject><subject>Diseases</subject><subject>Drug therapy</subject><subject>Ecuador</subject><subject>Endoscopy</subject><subject>Ethics</subject><subject>Hungary</subject><subject>Italy</subject><subject>Kinases</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Remission (Medicine)</subject><subject>Russia</subject><subject>Steroids</subject><subject>Tofacitinib</subject><subject>Ulcerative colitis</subject><issn>2077-0383</issn><issn>2077-0383</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNptUUtLxDAQLqKgqCf_QMCjVvNqm_W2rO8Hgqt4LGky0SzdZE2ywt78B579e_4SqxVUcOYww3yPgZks2yJ4j7EB3p-oKWGUVwLzpWyN4qrKMRNs-Ve_mm3GOMFdCMEpqday1xuQbX7vQ6vRkTGgkn0GBzEi6TQaSwNpgbxBY2h7DJ0PL9CZe7SNTT5EZB26axUE-QWOfGuT7cWj4B_d-8tbRIc2goxwgIboBlLwcdZ77aKreZusApcCoHGa68VGtmJkG2Hzu65nd8dHt6PT_PL65Gw0vMwVKQXPwTChy0JiQbnm5QAT2lQVDKBoMAOldSW1YYo2oDFAYagqMG8Mb4iUtCk1W8-2e99Z8E9ziKme-Hlw3cqaET4oOSuq4of1IFuorTM-BammNqp6KCgRTGBCOtbeP6wuNUyt8g6M7eZ_BDu9QHW3iAFMPQt2KsOiJrj-_GX965fsA44hkqM</recordid><startdate>20241201</startdate><enddate>20241201</enddate><creator>Farkas, Bernadett</creator><creator>Bessissow, Talat</creator><creator>Limdi, Jimmy K</creator><creator>Sethi-Arora, Karishma</creator><creator>Kagramanova, Anna</creator><creator>Knyazev, Oleg</creator><creator>Bezzio, Cristina</creator><creator>Armuzzi, Alessandro</creator><creator>Lukas, Milan</creator><creator>Michalopoulos, George</creator><creator>Chaskova, Elena</creator><creator>Savarino, Edoardo Vincenzo</creator><creator>Castiglione, Fabiana</creator><creator>Rispo, Antonio</creator><creator>Schäfer, Eszter</creator><creator>Saibeni, Simone</creator><creator>Filip, Rafal</creator><creator>Attauabi, Mohamed</creator><creator>Fousekis, Fotios S</creator><creator>Bacsur, Péter</creator><creator>Resál, Tamás</creator><creator>Bálint, Anita</creator><creator>Ivány, Emese</creator><creator>Szepes, Zoltán</creator><creator>Bősze, Zsófia</creator><creator>Fábián, Anna</creator><creator>Bor, Renáta</creator><creator>Farkas, Klaudia</creator><creator>Lakatos, Peter L</creator><creator>Molnár, Tamás</creator><general>MDPI AG</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><orcidid>https://orcid.org/0000-0002-3948-6488</orcidid><orcidid>https://orcid.org/0000-0003-0323-7030</orcidid><orcidid>https://orcid.org/0009-0007-8816-0138</orcidid><orcidid>https://orcid.org/0000-0002-1454-2412</orcidid><orcidid>https://orcid.org/0000-0002-3187-2894</orcidid><orcidid>https://orcid.org/0000-0001-5677-2534</orcidid><orcidid>https://orcid.org/0000-0002-3818-6205</orcidid><orcidid>https://orcid.org/0000-0002-8534-0068</orcidid><orcidid>https://orcid.org/0000-0003-1572-0118</orcidid><orcidid>https://orcid.org/0000-0002-5954-151X</orcidid></search><sort><creationdate>20241201</creationdate><title>Real-World Effectiveness and Safety of Selective JAK Inhibitors in Ulcerative Colitis and Crohn’s Disease: A Retrospective, Multicentre Study</title><author>Farkas, Bernadett ; Bessissow, Talat ; Limdi, Jimmy K ; Sethi-Arora, Karishma ; Kagramanova, Anna ; Knyazev, Oleg ; Bezzio, Cristina ; Armuzzi, Alessandro ; Lukas, Milan ; Michalopoulos, George ; Chaskova, Elena ; Savarino, Edoardo Vincenzo ; Castiglione, Fabiana ; Rispo, Antonio ; Schäfer, Eszter ; Saibeni, Simone ; Filip, Rafal ; Attauabi, Mohamed ; Fousekis, Fotios S ; Bacsur, Péter ; Resál, Tamás ; Bálint, Anita ; Ivány, Emese ; Szepes, Zoltán ; Bősze, Zsófia ; Fábián, Anna ; Bor, Renáta ; Farkas, Klaudia ; Lakatos, Peter L ; Molnár, Tamás</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1684-ef38d65a0824d469012b77e9e5b03ecdd7adf3c2bed0ee5f2c504bf4b1aa2b6d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>C-reactive protein</topic><topic>Care and treatment</topic><topic>Colitis</topic><topic>Crohn's disease</topic><topic>Disease</topic><topic>Diseases</topic><topic>Drug therapy</topic><topic>Ecuador</topic><topic>Endoscopy</topic><topic>Ethics</topic><topic>Hungary</topic><topic>Italy</topic><topic>Kinases</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Remission (Medicine)</topic><topic>Russia</topic><topic>Steroids</topic><topic>Tofacitinib</topic><topic>Ulcerative colitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Farkas, Bernadett</creatorcontrib><creatorcontrib>Bessissow, Talat</creatorcontrib><creatorcontrib>Limdi, Jimmy K</creatorcontrib><creatorcontrib>Sethi-Arora, Karishma</creatorcontrib><creatorcontrib>Kagramanova, Anna</creatorcontrib><creatorcontrib>Knyazev, Oleg</creatorcontrib><creatorcontrib>Bezzio, Cristina</creatorcontrib><creatorcontrib>Armuzzi, Alessandro</creatorcontrib><creatorcontrib>Lukas, Milan</creatorcontrib><creatorcontrib>Michalopoulos, George</creatorcontrib><creatorcontrib>Chaskova, Elena</creatorcontrib><creatorcontrib>Savarino, Edoardo Vincenzo</creatorcontrib><creatorcontrib>Castiglione, Fabiana</creatorcontrib><creatorcontrib>Rispo, Antonio</creatorcontrib><creatorcontrib>Schäfer, Eszter</creatorcontrib><creatorcontrib>Saibeni, Simone</creatorcontrib><creatorcontrib>Filip, Rafal</creatorcontrib><creatorcontrib>Attauabi, Mohamed</creatorcontrib><creatorcontrib>Fousekis, Fotios S</creatorcontrib><creatorcontrib>Bacsur, Péter</creatorcontrib><creatorcontrib>Resál, Tamás</creatorcontrib><creatorcontrib>Bálint, Anita</creatorcontrib><creatorcontrib>Ivány, Emese</creatorcontrib><creatorcontrib>Szepes, Zoltán</creatorcontrib><creatorcontrib>Bősze, Zsófia</creatorcontrib><creatorcontrib>Fábián, Anna</creatorcontrib><creatorcontrib>Bor, Renáta</creatorcontrib><creatorcontrib>Farkas, Klaudia</creatorcontrib><creatorcontrib>Lakatos, Peter L</creatorcontrib><creatorcontrib>Molnár, Tamás</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Journal of clinical medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Farkas, Bernadett</au><au>Bessissow, Talat</au><au>Limdi, Jimmy K</au><au>Sethi-Arora, Karishma</au><au>Kagramanova, Anna</au><au>Knyazev, Oleg</au><au>Bezzio, Cristina</au><au>Armuzzi, Alessandro</au><au>Lukas, Milan</au><au>Michalopoulos, George</au><au>Chaskova, Elena</au><au>Savarino, Edoardo Vincenzo</au><au>Castiglione, Fabiana</au><au>Rispo, Antonio</au><au>Schäfer, Eszter</au><au>Saibeni, Simone</au><au>Filip, Rafal</au><au>Attauabi, Mohamed</au><au>Fousekis, Fotios S</au><au>Bacsur, Péter</au><au>Resál, Tamás</au><au>Bálint, Anita</au><au>Ivány, Emese</au><au>Szepes, Zoltán</au><au>Bősze, Zsófia</au><au>Fábián, Anna</au><au>Bor, Renáta</au><au>Farkas, Klaudia</au><au>Lakatos, Peter L</au><au>Molnár, Tamás</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Real-World Effectiveness and Safety of Selective JAK Inhibitors in Ulcerative Colitis and Crohn’s Disease: A Retrospective, Multicentre Study</atitle><jtitle>Journal of clinical medicine</jtitle><date>2024-12-01</date><risdate>2024</risdate><volume>13</volume><issue>24</issue><spage>7804</spage><pages>7804-</pages><issn>2077-0383</issn><eissn>2077-0383</eissn><abstract>Background/Objectives: Data on the real-world effectiveness and safety of selective JAK inhibitors (JAKis) in ulcerative colitis (UC) and Crohn’s disease (CD) are limited. Methods: We conducted a multicentre, retrospective study to assess clinical, biochemical, and endoscopic outcomes of selective JAKis in bio-experienced UC and CD. Results: A total of 246 patients (mean age: 40.5 ± 14.5 years; 131 UC and 115 CD) were included with a median follow-up of 7.5 months. Among the CD patients receiving upadacitinib (n = 115), 76.2% achieved clinical remission (CR) at week 12. Furthermore, 59.5% of the upadacitinib-treated UC patients (n = 100) experienced CR at week 8. Corticosteroid-free CR (CSFCR) was achieved by 76.9% of the CD patients and 80.6% of the UC patients at week 24, while 50.0% and 36.1% experienced endoscopic remission. At week 52, 66.7% of the CD and 86.2% of the UC patients achieved CSFCR, whereas 54.5% and 52.9% had endoscopic remission. In UC, the effectiveness of upadacitinib was not compromised by prior tofacitinib failure, while the upadacitinib-treated CD patients with stricturing and penetrating disease were less likely to achieve CR by the end of the induction phase (p = 0.04). C-reactive protein (p[CD] < 0.0001; p[UC] < 0.0001) and faecal calprotectin (p[CD] < 0.0001; p[UC] = 0.02) decreased significantly in both patient groups as early as week 2. Among the filgotinib-treated UC patients (n = 31), 28.6% were in CR at week 12. At week 24 and 52, 59.1% and 60% achieved CSFCR, while 0.0% and 20.0% had endoscopic remission. Both C-reactive protein (p = 0.04) and faecal calprotectin (p = 0.04) decreased significantly by week 12. Hyperlipidaemia (9.7–9.8%) was the most common adverse event. Conclusions: Selective JAKis are rapidly effective and safe for treating refractory, moderate-to-severe CD and UC.</abstract><cop>Basel</cop><pub>MDPI AG</pub><doi>10.3390/jcm13247804</doi><orcidid>https://orcid.org/0000-0002-3948-6488</orcidid><orcidid>https://orcid.org/0000-0003-0323-7030</orcidid><orcidid>https://orcid.org/0009-0007-8816-0138</orcidid><orcidid>https://orcid.org/0000-0002-1454-2412</orcidid><orcidid>https://orcid.org/0000-0002-3187-2894</orcidid><orcidid>https://orcid.org/0000-0001-5677-2534</orcidid><orcidid>https://orcid.org/0000-0002-3818-6205</orcidid><orcidid>https://orcid.org/0000-0002-8534-0068</orcidid><orcidid>https://orcid.org/0000-0003-1572-0118</orcidid><orcidid>https://orcid.org/0000-0002-5954-151X</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2077-0383 |
ispartof | Journal of clinical medicine, 2024-12, Vol.13 (24), p.7804 |
issn | 2077-0383 2077-0383 |
language | eng |
recordid | cdi_proquest_journals_3149643575 |
source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; PubMed Central |
subjects | C-reactive protein Care and treatment Colitis Crohn's disease Disease Diseases Drug therapy Ecuador Endoscopy Ethics Hungary Italy Kinases Medical research Medicine, Experimental Patient outcomes Patients Remission (Medicine) Russia Steroids Tofacitinib Ulcerative colitis |
title | Real-World Effectiveness and Safety of Selective JAK Inhibitors in Ulcerative Colitis and Crohn’s Disease: A Retrospective, Multicentre Study |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T06%3A38%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Real-World%20Effectiveness%20and%20Safety%20of%20Selective%20JAK%20Inhibitors%20in%20Ulcerative%20Colitis%20and%20Crohn%E2%80%99s%20Disease:%20A%20Retrospective,%20Multicentre%20Study&rft.jtitle=Journal%20of%20clinical%20medicine&rft.au=Farkas,%20Bernadett&rft.date=2024-12-01&rft.volume=13&rft.issue=24&rft.spage=7804&rft.pages=7804-&rft.issn=2077-0383&rft.eissn=2077-0383&rft_id=info:doi/10.3390/jcm13247804&rft_dat=%3Cgale_proqu%3EA821838011%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3149643575&rft_id=info:pmid/&rft_galeid=A821838011&rfr_iscdi=true |